Blood Pressure Management for Stroke Prevention and in Acute Stroke

Elevated blood pressure (BP) is the leading modifiable risk factor for stroke and the benefit of BP lowering therapy on the stroke risk reduction is well established. The optimal BP target for preventing stroke and other vascular events have been controversial, but the evidences from epidemiological...

Full description

Saved in:
Bibliographic Details
Published inJournal of stroke Vol. 19; no. 2; pp. 152 - 165
Main Author Hong, Keun-Sik
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Stroke Society 01.05.2017
대한뇌졸중학회
Subjects
Online AccessGet full text
ISSN2287-6391
1229-4101
2287-6405
DOI10.5853/jos.2017.00164

Cover

More Information
Summary:Elevated blood pressure (BP) is the leading modifiable risk factor for stroke and the benefit of BP lowering therapy on the stroke risk reduction is well established. The optimal BP target for preventing stroke and other vascular events have been controversial, but the evidences from epidemiological studies and randomized controlled trials (RCTs) support intensive BP lowering for greater vascular protection, particularly for stroke prevention. For secondary stroke prevention, the evidence of intensive BP lowering benefit is limited since only a single RCT for patients with lacunar infarctions was conducted and most data were driven by exploratory analyses. In acute intracerebral hemorrhage, immediate BP lowering targeting systolic BP<140 mm Hg is recommended by guidelines based on the results from RCTs. In contrast, in acute ischemic stroke, early BP lowering is not usually recommended because of no benefit on functional outcome and future vascular events and potential harm of stroke progression. This review aims to summarize the updated evidence for optimal BP management for primary and secondary stroke prevention and in patients with acute stroke.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Dr. Keun-Sik Hong has received lecture honoraria from Daiichi-Sankyo Korea, Pfizer Korea, Boehringer Ingelheim Korea, Boryung Pharm, and Hanmi Pharm related to the current topic.
ISSN:2287-6391
1229-4101
2287-6405
DOI:10.5853/jos.2017.00164